Left Main Coronary Disease (LMCA Disease)
Details of the Concept
Unprotected left main coronary artery (LMCA) disease is defined as ≥50% stenosis of the left main coronary artery in the absence of a patent bypass graft to the LAD or LCx. It is detected in 4–6% of patients undergoing diagnostic coronary angiography and is associated with substantial myocardial ischaemia and adverse prognosis due to the large territory of myocardium supplied. CABG has historically been the preferred revascularisation strategy, but randomised trials (EXCEL, NOBLE, PRECOMBAT, SYNTAX) have established PCI as an acceptable alternative for patients with low-to-intermediate anatomical complexity (SYNTAX score ≤32–33). PCI for LMCA disease poses technical challenges including ensuring adequate stent expansion, apposition, and lesion coverage — particularly at the bifurcation of the LAD and LCx.
Key Facts
Epidemiology and Risk
- Prevalence: 4–6% of patients undergoing diagnostic coronary angiography
- Associated with high ischaemic burden; adverse prognosis if untreated
- Contemporary PCI for LMCA uses second-generation DES; stent thrombosis rates are low (<1%) with modern techniques
- OPTIMAL trial: mean SYNTAX score 29.7±12.6 — higher than EXCEL (26.5), NOBLE (22.5), PRECOMBAT (24.4); reflects contemporary real-world practice with more complex and inoperable patients (sources/ivus-optimal-nejm-2026, rating: high)
Revascularisation Strategy
- CABG preferred for SYNTAX score >33 and/or diabetes with multivessel disease (COR 1/B-R per AHA guidelines) (sources/ACS-AHA-2025, rating: very high)
- PCI acceptable for low-to-intermediate complexity LMCA disease (SYNTAX ≤32–33; no diabetes + multivessel disease) — EXCEL, NOBLE, PRECOMBAT trials demonstrate similar MACE at 5 years (sources/ACS-AHA-2025, rating: very high)
- Bifurcation strategy (provisional single-stent vs two-stent technique) selected at operator discretion; proximal optimisation technique (POT) recommended to ensure adequate proximal LMCA stent expansion
- Heart team decision-making required (COR 1/B-NR per guidelines) (sources/ACS-AHA-2025, rating: very high)
IVUS Guidance in LMCA PCI — Pre-2026 Recommendation
- Observational data and meta-analyses showed IVUS guidance associated with lower death, MI, and stent thrombosis in LMCA PCI
- IVUS used in >50% of LMCA PCI procedures in contemporary practice
- 2024 ESC Chronic Coronary Syndromes Guidelines and 2025 ACC/AHA ACS Guidelines both endorsed intracoronary imaging (IVUS or OCT) for complex PCI including left main disease as Class IA recommendation (sources/ACS-AHA-2025, rating: very high)
OPTIMAL Trial — Challenging the IVUS Mandate (2026)
- First large RCT specifically testing IVUS guidance in unprotected LMCA PCI (N=806; 28 European centres; median follow-up 2.9 years) (sources/ivus-optimal-nejm-2026, rating: high)
- IVUS-guided PCI used mandatory post-stent IVUS with prespecified minimum lumen area targets: LMCA body ≥8 mm², bifurcation ≥7 mm², proximal LAD/LCx ≥6 mm², proximal LCx ≥5 mm²
- Primary outcome (patient-oriented composite: stroke/MI/revascularisation/death): 33.7% vs 30.9%; HR 1.11 (95% CI 0.87–1.42); P=0.40 — no superiority of IVUS guidance
- No difference in device-oriented composite, vessel-oriented composite, death, MI, or repeat revascularisation
- Unexpected stroke signal: 3.0% (IVUS) vs 1.0% (angiography); HR 3.11 — considered possibly chance given low event numbers and unexplained mechanism; onset median 19 months post-procedure
- Conclusion: angiography-guided PCI may be appropriate when performed by expert IVUS operators at high-volume centres (sources/ivus-optimal-nejm-2026, rating: high)
Contradictions / Open Questions
- Class IA guideline vs OPTIMAL trial: Current guidelines recommend IVUS/OCT as Class IA for LMCA PCI, based on pre-2026 observational and indirect evidence. OPTIMAL (NEJM 2026) found no superiority of IVUS guidance at 2.9 years in a dedicated LMCA RCT. This is the most direct contradiction of a current Class IA recommendation in the PCI field. Future guideline revision expected. (sources/ivus-optimal-nejm-2026, rating: high; sources/ACS-AHA-2025, rating: very high)
- Expertise confounding: OPTIMAL operators used IVUS in 50–100% of LMCA PCIs in routine practice before the trial — the angiography arm may have benefited from operators who already internalised IVUS-derived anatomical knowledge. Whether IVUS guidance adds value in lower-expertise settings is unknown.
- SYNTAX score ≥33 subgroup: OPTIMAL enrolled patients with mean SYNTAX 29.7; benefit of IVUS specifically in patients with very high SYNTAX (the highest-risk group least suited for CABG) is uncharacterised.
- PCI vs CABG decision not addressed: OPTIMAL does not address the CABG vs PCI choice; SYNTAX score ≥33 still favours CABG regardless of imaging strategy.
- Stroke signal (HR 3.11): Unexplained; onset 19 months post-procedure argues against periprocedural mechanism; possibly chance. Requires replication in future data. (sources/ivus-optimal-nejm-2026, rating: high)
Connections
- Related to concepts/Intracoronary-Imaging-Guided-PCI — OPTIMAL trial directly addresses IVUS guidance in this entity
- Related to entities/Chronic-Coronary-Disease — CCS patients comprise the majority of stable LMCA PCI candidates
- Related to entities/Acute-Coronary-Syndrome — NSTEMI/UA account for 49.2% of OPTIMAL enrolment